Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
2,000 participants
Jan 16, 2017
INTERVENTIONAL
Conditions
Summary
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.
Eligibility
Inclusion Criteria8
- Patients with idiopathic cytopenias of unclear significance (ICUS)
- Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
- Patients with clonal cytopenias of undetermined significance (CCUS)
- Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
- Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
- Low risk MDS (idiopathic dysplasia of unclear significance)
- Family member of a patient with one of the above conditions
- Patient at high risk or suspected of developing one of the above conditions
Exclusion Criteria1
- Patients under 18 years of age
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo blood sample, hair follicle, and saliva collection
Undergo a bone marrow biopsy
Undergo a skin punch biopsy
Undergo a saliva or buccal swab
Undergo clinical assessment
Receive genetic counseling
Ancillary studies
Ancillary studies
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02958462